Overview

Cogent Biosciences develops small molecule therapies for rare, genetically driven diseases. Its work centers on discovering and advancing compounds that can address conditions with limited treatment options, using a research-driven approach to guide drug discovery and development through clinical trials. The lead candidate, CGT9486, is progressing in three clinical trials planned for this year, alongside ongoing work in collaboration with partners. The company differentiates itself through its focus on genetically defined diseases, its emphasis on targeted small molecules, and its strategy of advancing candidates via internal science and partnerships, supported by a strong financial position that includes a cash reserve of $242.2 million. Cogent’s goal is to bring effective therapies to patients with unmet needs by progressing its drug candidates toward potential commercialization and forming strategic collaborations to maximize development and access.